CyberArk Software Ltd. (CYBR)
NASDAQ: CYBR · Real-Time Price · USD
409.00
-5.00 (-1.21%)
At close: Aug 4, 2025, 4:00 PM
409.23
+0.23 (0.06%)
After-hours: Aug 4, 2025, 7:32 PM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 32 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $425.31, which forecasts a 3.99% increase in the stock price over the next year. The lowest target is $300 and the highest is $551.
Price Target: $425.31 (+3.99%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 16 | 15 | 15 | 12 | 11 |
| Buy | 15 | 17 | 17 | 17 | 13 | 12 |
| Hold | 1 | 1 | 1 | 1 | 9 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 31 | 34 | 33 | 33 | 34 | 36 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 1, 2025 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 1, 2025 |
| Rosenblatt | Rosenblatt | Strong Buy → Hold Downgrades $445 | Strong Buy → Hold | Downgrades | $445 | +8.80% | Aug 1, 2025 |
| Baird | Baird | Buy → Hold Downgrades $460 | Buy → Hold | Downgrades | $460 | +12.47% | Aug 1, 2025 |
| Keybanc | Keybanc | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 31, 2025 |
Financial Forecast
Revenue This Year
1.35B
from 1.00B
Increased by 34.80%
Revenue Next Year
1.61B
from 1.35B
Increased by 19.64%
EPS This Year
3.92
from -2.12
EPS Next Year
4.98
from 3.92
Increased by 27.14%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.4B | 1.7B | 2.1B | ||
| Avg | 1.3B | 1.6B | 1.9B | ||
| Low | 1.3B | 1.5B | 1.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.5% | 29.1% | 31.8% | ||
| Avg | 34.8% | 19.6% | 20.6% | ||
| Low | 28.8% | 10.7% | 8.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 5.05 | 6.39 | 9.86 |
| Avg | 3.92 | 4.98 | 6.71 |
| Low | 3.69 | 4.33 | 5.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 63.3% | 98.0% |
| Avg | - | 27.1% | 34.8% |
| Low | - | 10.6% | 13.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.